WGRX

Company Overview — What Does Wellgistics Health, Inc. Do?

Founded in 2022, Wellgistics Health is a holding company for various existing and planned strategic businesses centered around pharmaceuticals and healthcare services. As a micro health ecosystem, our portfolio of companies consists of a pharmacy, wholesale operations, and a technology division with a novel platform for hub and clinical services. We are focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. In January 2023 and May 2023, Wellgistics Health entered into separate definitive agreements with the owners of Wood Sage and Wellgistics LLC, respectively, whereby Wellgistics Health would acquire all of the respective outstanding membership interests of Wood Sage and Wellgistics LLC. In June 2024, Wellgistics Health and Wood Sage entered into an amended and revised definitive agreement and closed on the Wood Sage Acquisition, thereby making Wood Sage a wholly owned subsidiary of Wellgistics Health. In connection with the Wood Sage Acquisition, Wellgistics Health acquired Wood Sage’s two operating subsidiaries, APS—a pharmaceutical technology hub—and CSP—a retail community specialty pharmacy. On August 30, 2024, Wellgistics Health closed on the Wellgistics Acquisition, thereby making Wellgistics LLC—a company focused on wholesale operations including the distribution and fulfillment of certain pharmaceutical medications to a network of independent pharmacies meant to improve market access to and patient outcomes regarding the medications—a wholly owned subsidiary of Wellgistics Health. As such, Wellgistics Health currently exists as a holding company with Wood Sage as a directly held intermediate holding company subsidiary, APS and CSP as indirect operating subsidiaries, and Wellgistics LLC as a direct operating subsidiary. On October 4, 2024, the Company changed its corporate name to “Wellgistics Health, Inc.” by filing a duly authorized Certificate of Amendment to its Certificate of Incorporation. Despite that Wellgistics Health only recently closed the Wood Sage Acquisition and the Wellgistics Acquisition during 2024, the three companies have shared common office space, comarketed solutions to the marketplace, and leveraged financial and back-office support prior to June 2024. As such, Wellgistics Health’s management believes that its close business relationships have and will continue to limit the need for post-closing integration. The mailing address of our principal executive office is 3000 Bayport Drive, Suite 950 Tampa, FL. Wellgistics Health, Inc. (WGRX) is classified as a micro-cap stock in the Consumer Staples sector, specifically within the Wholesale industry. The company is led by CEO Tim Canning and employs approximately 31 people, headquartered in TAMPA, Florida. With a market capitalization of $11M, WGRX is one of the notable companies in the Consumer Staples sector.

Wellgistics Health, Inc. (WGRX) Stock Rating — Avoid (April 2026)

As of April 2026, Wellgistics Health, Inc. receives a Avoid rating with a composite score of 17.7/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.WGRX ranks #4,374 out of 4,446 stocks in our coverage universe. Within the Consumer Staples sector, Wellgistics Health, Inc. ranks #178 of 180 stocks, placing it in the lower half of its Consumer Staples peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

WGRX Stock Price and 52-Week Range

Wellgistics Health, Inc. (WGRX) currently trades at $0.12. The stock gained $0.01 (13.8%) in the most recent trading session. The 52-week high for WGRX is $7.04, which means the stock is currently trading -98.3% from its annual peak. The 52-week low is $0.13, putting the stock -6.6% above its annual trough. Recent trading volume was 215.1M shares, indicating strong institutional interest and high liquidity.

Is WGRX Overvalued or Undervalued? — Valuation Analysis

Wellgistics Health, Inc. (WGRX) carries a value factor score of 7/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.81x, versus the sector average of 1.74x. The price-to-sales ratio is 0.16x, compared to 0.35x for the average Consumer Staples stock.

At current multiples, Wellgistics Health, Inc. trades at a premium to most Consumer Staples peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Wellgistics Health, Inc. Profitability — ROE, Margins, and Quality Score

Wellgistics Health, Inc. (WGRX) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -2025.3%, compared to the Consumer Staples sector average of 7.7%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -1330.0% versus the sector average of 3.1%.

On a margin basis, Wellgistics Health, Inc. reports gross margins of -27.5%, compared to 26.2% for the sector. The operating margin is -401.7% (sector: 2.9%). Net profit margin stands at -433.9%, versus 1.6% for the average Consumer Staples stock. Revenue growth is running at -46.9% on a trailing basis, compared to 3.1% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

WGRX Debt, Balance Sheet, and Financial Health

Wellgistics Health, Inc. has a debt-to-equity ratio of 366.0%, compared to the Consumer Staples sector average of 72.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 0.09x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $23M. Cash and equivalents stand at $4M.

WGRX has a beta of 1.39, meaning it is more volatile than the broader market — a $10,000 investment in WGRX would be expected to move 39.2% more than the S&P 500 on any given day. The stability factor score for Wellgistics Health, Inc. is 13/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Wellgistics Health, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Wellgistics Health, Inc. reported revenue of $23M and earnings per share (EPS) of $-1.43. Net income for the quarter was $-101M. Gross margin was -27.5%. Operating income came in at $-94M.

In FY 2025, Wellgistics Health, Inc. reported revenue of $23M and earnings per share (EPS) of $-1.43. Net income for the quarter was $-101M. Gross margin was -27.5%. Revenue grew 28.7% year-over-year compared to FY 2024. Operating income came in at $-94M.

In Q3 2025, Wellgistics Health, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.46. Net income for the quarter was $-34M. Gross margin was 7.7%. Operating income came in at $-32M.

In Q2 2025, Wellgistics Health, Inc. reported revenue of $8M and earnings per share (EPS) of $-0.11. Net income for the quarter was $-7M. Gross margin was 6.5%. Operating income came in at $-6M.

Over the past 7 quarters, Wellgistics Health, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $23M. Investors analyzing WGRX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

WGRX Dividend Yield and Income Analysis

Wellgistics Health, Inc. (WGRX) does not currently pay a dividend. This is common among smaller companies in the Wholesale industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Consumer Staples dividend stocks may want to explore other Consumer Staples stocks or use the stock screener to filter by dividend yield.

WGRX Momentum and Technical Analysis Profile

Wellgistics Health, Inc. (WGRX) has a momentum factor score of 6/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 50/100 reflects moderate short selling activity.

WGRX vs Competitors — Consumer Staples Sector Ranking and Peer Comparison

Within the Consumer Staples sector, Wellgistics Health, Inc. (WGRX) ranks #178 out of 180 stocks based on the Blank Capital composite score. This places WGRX in the lower half of all Consumer Staples stocks in our coverage universe. Key competitors and sector peers include Ituran Location & Control Ltd. (ITRN) with a score of 60.3/100, DARLING INGREDIENTS INC. (DAR) with a score of 52.9/100, Bunge Global SA (BG) with a score of 53.0/100, SANFILIPPO JOHN B & SON INC (JBSS) with a score of 54.1/100, and Archer-Daniels-Midland Co (ADM) with a score of 52.2/100.

Comparing WGRX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full WGRX vs S&P 500 (SPY) comparison to assess how Wellgistics Health, Inc. stacks up against the broader market across all factor dimensions.

WGRX Next Earnings Date

No upcoming earnings date has been announced for Wellgistics Health, Inc. (WGRX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy WGRX? — Investment Thesis Summary

The quantitative profile for Wellgistics Health, Inc. suggests caution. The quality score of 21/100 flags below-average profitability. The value score of 7/100 indicates premium valuation. Momentum is weak at 6/100, a headwind for near-term performance. High volatility (stability score 13/100) increases portfolio risk.

In summary, Wellgistics Health, Inc. (WGRX) earns a Avoid rating with a composite score of 17.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on WGRX stock.

Related Resources for WGRX Investors

Explore more research and tools: WGRX vs S&P 500 comparison, top Consumer Staples stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare WGRX head-to-head with peers: WGRX vs ITRN, WGRX vs DAR, WGRX vs BG.